As of today (2024-04-28), aTyr Pharma's share price is $1.57.
aTyr Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.67. Hence, aTyr Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for aTyr Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:
LIFE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.52 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 25.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 42.40% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 34.20% per year.
During the past 11 years, aTyr Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 58.50% per year. The lowest was -8.20% per year. And the median was 31.05% per year.
aTyr Pharma Price-to-Free-Cash-Flow Historical Data
The historical data trend for aTyr Pharma's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of aTyr Pharma's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, aTyr Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Price-to-Free-Cash-Flow falls into.
aTyr Pharma Price-to-Free-Cash-Flow Calculation
aTyr Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as
aTyr Pharma's Share Price of today is $1.57. aTyr Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
aTyr Pharma Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of aTyr Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 